Nonpigmented fixed drug eruption induced by esomeprazole

Cutaneous and Ocular Toxicology

Volumn 29, Issue 3, 2010, Pages 217-220

  Morais, Paulo ^a,b   Baudrier, Teresa ^a   Mota, Alberto ^a,b   Cunha, Ana Paula ^a,b   Cadinha, Susana ^a   Barros, Ana Margarida ^a   Azevedo, Filomena ^a  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

Esomeprazole; fixed drug eruption; oral controlled provocation test; patch test; skin eruption

Indexed keywords

ESOMEPRAZOLE; PETROLATUM; PREDNISOLONE; RANITIDINE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CASE REPORT; DERMATITIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HUMAN; LUMBOSACRAL SPINE; LYMPHOCYTIC INFILTRATION; MAMMARY GLAND; NONPIGMENTED FIXED DRUG ERUPTION; PATCH TEST; PROVOCATION TEST; PUBIC BONE; SKIN BIOPSY; SKIN PRURITUS; SPONGIOTIC DERMATITIS; MIDDLE AGED; PATHOLOGY; REFLUX ESOPHAGITIS; SKIN PIGMENTATION; TREATMENT OUTCOME;

DRUG ERUPTIONS; ESOPHAGITIS, PEPTIC; FEMALE; HUMANS; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; SKIN PIGMENTATION; TREATMENT OUTCOME;

EID: 77955112645     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.3109/15569527.2010.484824     Document Type: Article

References (16)

1. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008; 64:935-951.
2. Vachhani R, Olds G, Velanovich V. Esomeprazole: a proton pump inhibitor. Expert Rev Gastroenterol Hepatol 2009;3:15-27.
3. Johnson DA. Review of esomeprazole in the treatment of acid disorders. Expert Opin Pharmacother 2003; 4:253-264.
4. Barbaud A, Gonçalo M, Bruynzeel D, Bircher A. European Society of Contact Dermatitis. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001; 45:321-328.
5. Wilkinson DS, Fregert S, Magnusson B, Bandmann HJ, Calnan CD, Cronin E, et al. Terminology of contact dermatitis. Acta Derm Venereol 1970; 50:287-292.
6. U.S. Food and Drug Administration. Drugs@FDA: esomeprazole. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (accessed 15 January 2009).
7. Drugs.com. Nexium. http://www.drugs.com/pro/nexium. html (accessed 15 January 2009).
8. Maffei M, Desmeules J, Cereda JM, Hadengue A. [Effets indésirables des inhibiteurs de la pompe à protons (IPP)]. Rev Med Suisse 2007; 3:1934-1936,1938.
9. Gilger MA, Tolia V, Vandenplas Y, Youssef NN, Traxler B, Illueca M. Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2008; 46:524-533.
10. Gold BD, Gunasekaran T, Tolia V, Wetzler G, Conter H, Traxler B, et al. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007; 45:520-529.
11. Domínguez-Leñero V, Barrera-Ledesma M, Romero-Alonso M, Garrido Martínez MT. [Sí,ndrome de Stevens-Johnson y hepatitis tóxica por esomeprazol]. Farm Hosp 2009;33:118-119.
12. Caboni S, Gunera-Saad N, Ktiouet-Abassi S, Berard F, Nicolas JF. Esomeprazole-induced DRESS syndrome. Studies of crossreactivity among proton-pump inhibitor drugs. Allergy 2007; 62:1342-1343.
13. Garmendia Zallo M, Sánchez Azkarate A, Kraemer Mbula R, Liarte Ruano I, Nuñez Hernández A, Cid de Rivera C. [Existe reactividad cruzada entre inhibidores de la bomba de protones?] Allergol Immunopathol 2004; 32:92-95.
14. Pérez Pimiento AJ, Prieto Lastra L, Rodríguez Cabreros MI, González Sá,nchez LA, Mosquera MR, Cubero AG. Hypersensitivity to lansoprazole and rabeprazole with tolerance to other proton pump inhibitors. J Allergy Clin Immunol 2006; 117:707-708.
15. Schmutz J-L, Barbaud A, Tréchot P. [Inhibiteurs de la pompe à protons (IPP) et toxidermie photodistribuée]. Ann Dermatol Venereol 2007; 134:212.
16. Naranjo CA, Shear NH, Lanctôt KL. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol 1992; 32:897-904.